hotspot -WSS

hotspot

author：knowledge 2025-10-02 17:50:23 - browse：21911

Since the early days of the pandemic, long Covid has haunted us: Even a mild acute infection might leave you with life-altering consequences. And for many, that has, sadly, turned out to be the case. While research suggests long Covid rates are falling, it still affects millions. In June 2023, 6% of Americans reported experiencing long Covid.

But what if long Covid isn’t the right way to think about what they are going through?

On this episode of the First Opinion Podcast, I spoke with Steven Phillips and Michelle A. Williams, authors of a recent First Opinion essay titled, “Long Covid is a new name for an old syndrome.” Steven is a Global Virus Network board member and vice president for science and strategy at the COVID Collaborative; Michelle is the former dean and current Joan and Julius Jacobson professor of epidemiology and public health at the Harvard T.H. Chan School of Public Health.

“Michelle and I have come up with basically a new paradigm that says long Covid is really an old disease, and the more you do deep dives into the history of chronic fatigue syndrome and post-infectious fatigue syndromes, the more you realize that not only are there similarities, but the level of congruence between the two is strikingly high,” Steven said.

The purpose of this new paradigm is to “break the logjam” of the current long Covid discourse and “to try to provide a framework whereby people would think about long Covid in a different way in a way that would be more productive,” Michelle told me.

We discussed the history of post-infectious disease syndrome, what rethinking long Covid might mean for research, and the ways the health care system fails chronically ill patients.

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Spotify, Google Play, or wherever you get your podcasts.

Previous article： Drug repurposing or repositioning? The language matters
Next article： HHS secretary Becerra pressed on Change HealthCare cyberattack

WSS

Boston's new lab space is opening empty

Male and female sex labels in research insufficient, scientists say

John Green on his newest strategy for fighting tuberculosis

How many hemophilia patients actually want gene therapy?

FDA clears Verve to begin U.S. study of gene

STAT Readout Newsletter: Biotech news today

hotspot

hotspot

focus

DIEP, the 'gold standard' of breast reconstruction, is under threat

STAT Summit: How researchers deal with rejection

State Dept. review finds Biden bears some blame for Afghanistan failures

Health tech investors get more selective as pandemic boom fades

How to save PrEP access — and even expand it

ADCs take center stage as promising cancer treatments

Affirmative action in medical school literally saved lives

Smaller biotechs seek to piggyback on weight loss drug boom

Guidelines to prevent youth baseball injuries need more muscle

Is there really a nursing shortage in the U.S.?

focus

UnitedHealth, Optum discontinue NaviHealth name

Study on Amgen’s bispecific immunotherapy produces positive data

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

EPA limits use of carcinogenic gas for sterilizing medical devices

Roche acquires Telavant from Roivant, adding experimental IBD treatment

STAT Readout Newsletter: Biotech news today

hotspot

entertainment

explore

leisure time